Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biohaven Pharmaceuticals
Biotech
Biohaven reduces scope of R&D cuts as pipeline progresses
Biohaven is powering ahead with its ambition to cut R&D spending as analysts warn the company will need to be even stricter with its expenditures.
James Waldron
Mar 3, 2026 9:00am
How Biohaven is keeping its 'feet to the fire'
Feb 20, 2026 10:30am
Biohaven CEO calls recent FDA decisions 'a systemic problem'
Feb 13, 2026 4:14pm
2025's top 10 clinical trial flops
Feb 9, 2026 3:00am
Biohaven flunks depression trial, adding to CNS release concerns
Jan 2, 2026 4:48am
FDA rejects Biohaven approval request, triggering cost cutting
Nov 5, 2025 4:02am
